[EN] PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMEDICAMENTS D'ANALOGUES GABA, LEURS COMPOSITIONS ET UTILISATIONS
申请人:XENOPORT INC
公开号:WO2004052844A1
公开(公告)日:2004-06-24
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
[EN] PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMEDICAMENTS D'ANALOGUES DE GABA, COMPOSITIONS ET UTILISATIONS DESDITS PROMEDICAMENTS
申请人:XENOPORT INC
公开号:WO2002100347A2
公开(公告)日:2002-12-19
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using phannaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.
Engineering absorption of therapeutic compounds via colonic transporters
申请人:XenoPort, Inc.
公开号:US20030158254A1
公开(公告)日:2003-08-21
Methods of modifying therapeutic compounds such as drugs to be substrates for active transporters expressed in epithelial cells lining the lumen of the human colon are disclosed. The transporters expressed in the human colon include the sodium dependent multi-vitamin transporter (SMVT), and monocarboxylate transporters 1 and 4 (MCT 1 and MCT 4). The modified compounds can themselves be pharmacologically active, or upon cleavage of a chemical moiety after uptake from the colon, can be metabolized to form a compound that is pharmacologically active (e.g., a prodrug). The modified compounds disclosed herein are suitable for use in extended release oral dosage forms, particularly those that release drug over periods of greater than about 2-4 hours following administration.